| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MENLO PARK, Calif.—BillionToOne, a venture-backed precision diagnostics company, recently announced that its first product, UNITY, is now available for commercial and clinical use.
 
Powered by BillionToOne’s patent-pending molecular counting technology, UNITY is reportedly the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy (SMA) and sickle cell disease using just one tube of blood from the mother. With the completion of analytical and regulatory validation of UNITY, the company will make the test available at select clinics through its Early Access Program, with plans for a broader commercial launch later this year.
 
“We’re extremely excited about the commercial launch of UNITY, which will make the existing carrier screening process 10 times more accurate and efficient,” said Oguzhan Atay, CEO and co-founder of BillionToOne. “Making UNITY available through our Early Access Program will be the first step in ensuring that all mothers have access to the information they need to help them better prepare for a safe and healthy pregnancy.”
 
The American College of Obstetricians and Gynecologists (ACOG) recommends that every pregnant woman be screened for her carrier status for cystic fibrosis, SMA, sickle cell disease and thalassemias.
 
UNITY addresses the many challenges of traditional prenatal screening. It is the first carrier screening with reflex noninvasive prenatal testing for all ACOG-recommended disorders, meaning that once the mother is found to be a carrier, her blood is also analyzed to determine if her baby is at high risk for being affected by the genetic disorder. The entire UNITY screening process takes up to two weeks, compared to 12 weeks or more for traditional carrier screening—saving time and money for parents and reducing workflow for clinicians.   

Related Topics

Published In

Volume 15 - Issue 8 | August 2019

August 2019

August 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue